Trusted Resource for Clinical Trials, Protocols & Progress
Preparing the Market Authorization Application (MAA) and NDA from Phase 3 Data: Process, Content, and Global Insights How to Convert Phase 3 Trial Results into a Market Authorization Application (MAA) or NDA What Is an MAA or NDA? A Market Authorization Application (MAA) in Europe and a New Drug Application (NDA) in the United States…
Analyzing Intention-to-Treat vs Per-Protocol Populations – Clinical Trial Design and Protocol Development “Comparative Analysis of Intention-to-Treat and Per-Protocol Populations” Introduction In the world of clinical trials and pharmaceutical research, understanding and analyzing the intention-to-treat (ITT) and per-protocol (PP) populations is of paramount importance. The way these two groups are interpreted can significantly impact the results…
Role of Clinical Pharmacologists in Early Phase Trials How Clinical Pharmacologists Drive Strategy and Safety in Phase 1 Trials Introduction Clinical pharmacologists are at the heart of early-phase drug development. Their unique skill set, combining clinical medicine, pharmacokinetics (PK), pharmacodynamics (PD), and regulatory knowledge, makes them essential members of Phase 1 trial teams. From guiding…
Read More “Role of Clinical Pharmacologists in Early Phase Trials” »
Immunogenicity Assessments in Phase 2 Biologic Trials Evaluating Immunogenicity in Phase 2 Trials of Biologic Products Introduction Biologic therapies such as monoclonal antibodies, peptides, fusion proteins, and gene therapies have revolutionized treatment across oncology, autoimmune, and rare diseases. However, because they are derived from living organisms, biologics carry a unique risk: immunogenicity. This refers to…
Read More “Immunogenicity Assessments in Phase 2 Biologic Trials” »
Effectiveness Assessment in Subpopulations During Phase 4 Clinical Trials How Phase 4 Trials Evaluate Drug Effectiveness in Diverse and Underrepresented Subpopulations Introduction: The Role of Subpopulation Analysis in Post-Marketing Studies While randomized controlled trials (RCTs) in early phases of drug development aim to establish overall efficacy, they often exclude large segments of real-world patients. That’s…
Read More “Effectiveness Assessment in Subpopulations During Phase 4 Clinical Trials” »
When to Use Placebo Controls in RCTs – Clinical Trial Design and Protocol Development “Understanding the Appropriate Times to Utilize Placebo Controls in Randomized Controlled Trials” Introduction Randomized controlled trials (RCTs) form the cornerstone of clinical research, providing the highest level of evidence for the efficacy and safety of new treatments and interventions. A crucial…
Read More “When to Use Placebo Controls in RCTs – Clinical Trial Design and Protocol Development” »
Preparing for Regulatory Submission After Phase 3 Trials: Step-by-Step Strategy and Global Compliance How to Prepare and Organize Regulatory Submissions After Phase 3 Trials Why Regulatory Submission Is the Final Critical Step in Phase 3 Trials Once a Phase 3 clinical trial is completed and the database is locked, the next big milestone is regulatory…
Types of Randomization: Block, Stratified, and Adaptive – Clinical Trial Design and Protocol Development “Varieties of Randomization: Block, Adaptive, and Stratified” Introduction to Randomization in Clinical Studies Randomization in clinical studies is a fundamental aspect of research design aimed at minimizing bias and enhancing the validity of the study results. Through randomization, participants are randomly…
Phase 2 Studies in Rare Diseases: Design and Feasibility Challenges Designing Phase 2 Trials for Rare Diseases: Feasibility and Scientific Challenges Introduction Conducting clinical trials in rare diseases presents unique challenges that are especially pronounced in Phase 2, where early efficacy and dose optimization must be demonstrated. With small, geographically dispersed patient populations and limited…
Read More “Phase 2 Studies in Rare Diseases: Design and Feasibility Challenges” »
Safety Monitoring Boards and Safety Review Committees in Phase 1 Trials Safety Monitoring Boards and Safety Review Committees in Phase 1 Trials Introduction Safety is the cornerstone of every clinical trial, especially during early-phase drug development where human exposure to a new chemical or biological entity occurs for the first time. In Phase 1 studies,…
Read More “Safety Monitoring Boards and Safety Review Committees in Phase 1 Trials” »
